表紙
市場調査レポート

転移性肝癌:パイプライン製品の分析

Metastatic Liver Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229747
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
転移性肝癌:パイプライン製品の分析 Metastatic Liver Cancer - Pipeline Review, H2 2015
出版日: 2015年10月21日 ページ情報: 英文 58 Pages
概要

転移性肝癌は、肝臓以外の臓器にできた癌(原発巣)が肝臓に転移したものです。原発性肝癌の危険因子として、肝炎、肝硬変、肝臓の瘢痕化、男性、出生時の低体重が挙げられます。腹部右側のしこりや痛み、皮膚の黄変などの症状が見られます。肝臓癌は通常、肝臓の瘢痕化(肝硬変)によって引き起こされます。肝臓癌の治療には、化学療法、放射線療法、外科手術などが含まれます。

当レポートでは、転移性肝癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

転移性肝癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • F. Hoffmann-La Roche Ltd.
  • Celsion Corporation
  • Tekmira Pharmaceuticals Corp.
  • Arrowhead Research Corporation
  • Provectus Biopharmaceuticals, Inc.
  • Transgene Biotek Limited
  • Mirna Therapeutics, Inc.
  • PreScience Labs, LLC

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • RG-7686
  • rose bengal sodium
  • MRX-34
  • TKM-PLK1
  • PSL-001
  • doxorubicin liposomal
  • TBL-0404
  • Peptide Drug Conjugate For Metastatic Liver Cancer

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7255IDB

Summary

Global Markets Direct's, 'Metastatic Liver Cancer - Pipeline Review, H2 2015', provides an overview of the Metastatic Liver Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Liver Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Liver Cancer - Overview
    • Pipeline Products for Metastatic Liver Cancer - Comparative Analysis
  • Metastatic Liver Cancer - Therapeutics under Development by Companies
  • Metastatic Liver Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Liver Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Liver Cancer - Products under Development by Companies
  • Metastatic Liver Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Liver Cancer - Companies Involved in Therapeutics Development
    • AB Science SA
    • Arrowhead Research Corporation
    • Mirna Therapeutics, Inc.
    • Transgene Biotek Limited
  • Metastatic Liver Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • masitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-34 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncolytic Virus for Liver Metastases and Primary Liver Tumors - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Inhibit Hemofiltrate CC Chemokine for Metastatic Liver Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PSL-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TBL-0404 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Metastatic Liver Cancer - Recent Pipeline Updates
  • Metastatic Liver Cancer - Dormant Projects
  • Metastatic Liver Cancer - Discontinued Products
  • Metastatic Liver Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jul 02, 2015: AB Science: the Data and Safety Monitoring Board recommends continuation of three phase 2 studies
      • Jan 14, 2014: Mirna Therapeutics Reports Expansion of Intellectual Property Estate
      • Jul 24, 2013: PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Liver Cancer, H2 2015
  • Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Metastatic Liver Cancer - Pipeline by AB Science SA, H2 2015
  • Metastatic Liver Cancer - Pipeline by Arrowhead Research Corporation, H2 2015
  • Metastatic Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015
  • Metastatic Liver Cancer - Pipeline by Transgene Biotek Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Metastatic Liver Cancer Therapeutics - Recent Pipeline Updates, H2 2015
  • Metastatic Liver Cancer - Dormant Projects, H2 2015
  • Metastatic Liver Cancer - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Metastatic Liver Cancer, H2 2015
  • Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top